Find Clinical Trials

All CategoriesMedications / Interventions»Ee»Etoposide



Join Paid Clinical Trials



  • Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: mitoxantrone + etoposide + gemtuzumab ozogamicin
    Sponsor:   Michael Boyiadzis
    Recruiting

  • Conditions:   Leukemia;   Acute Myelogenous Leukemia;   Acute Myeloid Leukemia
    Interventions:   Drug: Ciprofloxacin;   Drug: Etoposide
    Sponsor:   University of Florida
    Recruiting

  • Condition:   Brain Tumor Recurrent
    Interventions:   Drug: Methotrexate;   Drug: Etoposide;   Procedure: Ommaya Reservoir
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Conditions:   ENSAT Stage I Adrenal Cortex Carcinoma;   ENSAT Stage II Adrenal Cortex Carcinoma;   ENSAT Stage III Adrenal Cortex Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Mitotane;   Procedure: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Amercian Australian Asian Adrenal Alliance (A5);   European Network for the Study of Adrenal Tumors (ENS@T)
    Recruiting

  • Conditions:   Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Allopurinol;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan
    Sponsor:   Swedish Medical Center
    Recruiting

  • Conditions:   Hematopoietic/Lymphoid Cancer;   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Burkitt Leukemia/Lymphoma
    Interventions:   Drug: Clofarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Liposomal Vincristine;   Drug: Bortezomib;   Drug: Ofatumumab;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Carfilzomib;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Amgen
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Sirolimus;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Minimal Residual Disease Negativity
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Small Cell Lung Cancer (SCLC)
    Interventions:   Biological: Pembrolizumab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiation therapy
    Sponsors:   New York University School of Medicine;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Prexasertib;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
    Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company
    Recruiting

  • Condition:   AML
    Interventions:   Drug: Etoposide;   Drug: Cytarabine;   Drug: Lenalidomide;   Drug: Mitoxantrone
    Sponsors:   Massachusetts General Hospital;   Celgene
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Primary Mediastinal B-cell Lymphoma;   CD20+ Lymphoblastic Lymphoma;   Follicular Lymphoma, Grade III
    Interventions:   Drug: Obinutuzumab;   Drug: Liposomal ARA-C;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
    Sponsors:   New York Medical College;   Roswell Park Cancer Institute
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Interventions:   Drug: Cyclophosphamide;   Drug: Etoposide;   Procedure: NK Cell Infusion;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Neuroendocrine Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   High Grade Neuroendocrine Carcinoma, Any Site
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Ochsner Health System;   Merck Sharp & Dohme Corp.
    Not yet recruiting

  • Condition:   Primary Central Nervious System Lymphoma
    Interventions:   Drug: Isavuconazole;   Drug: TEDDI;   Biological: Rituximab (R);   Drug: Cytarabine;   Drug: TEDD;   Drug: Ibrutinib (Arms 2 and 3);   Drug: Ibrutinib (Arm 1 - Closed with Amendment G)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Transformed Indolent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Venetoclax
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Carcinoma, Small Cell;   Carcinoma, Small Cell Lung
    Interventions:   Combination Product: RRx-001 + eLOOP Device;   Drug: Cisplatin/carboplatin plus etoposide
    Sponsor:   EpicentRx, Inc.
    Recruiting

  • Condition:   Mantle-Cell Lymphoma
    Interventions:   Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
    Sponsor:   University of Miami
    Recruiting

  • Conditions:   Glioma;   Pilocytic Astrocytoma;   Anaplastic Astrocytoma;   Glioblastoma;   Mixed Oligoastrocytoma;   Mixed Glioma;   Oligodendroglioma;   Optic Glioma;   Astrocytoma
    Interventions:   Device: MRI-guided laser ablation;   Drug: Doxorubicin;   Drug: Etoposide;   Device: Dynamic contrast-enhanced (DCE) MRI;   Device: Dynamic susceptibility contrast (DSC) MRI
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Autoimmune Disease
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Everolimus;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Lymphatic Diseases
    Interventions:   Drug: Brentuximab Vedotin;   Drug: CHEP
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present;   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: BeEAM
    Sponsors:   Northside Hospital, Inc.;   Teva Pharmaceuticals USA
    Recruiting

  • Condition:   Lymphoma
    Interventions:   Radiation: Radiation Therapy;   Drug: Dexamethasone;   Drug: Etoposide phosphate;   Drug: Ifosfamide;   Drug: Mesna;   Drug: Carboplatin
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
    Sponsors:   Washington University School of Medicine;   Amgen
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Etoposide;   Biological: Rituximab;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Melphalan;   Other: Autologous HSCT;   Drug: Acalabrutinib
    Sponsors:   Swedish Medical Center;   Acerta Pharma BV
    Not yet recruiting

  • Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Castration-Resistant Prostate Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Prostate Neuroendocrine Neoplasm;   Prostate Small Cell Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage III Urethral Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Ureter Small Cell Carcinoma;   Urothelial Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Etoposide;   Biological: Pembrolizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Yttrium Y 90 Basiliximab;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Carmustine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Cytarabine;   Drug: Alemtuzumab;   Biological: Autologous Stem Cell Transplantation;   Biological: Allogeneic Stem Cell Transplantation;   Drug: Rituximab
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
    Sponsors:   Weill Medical College of Cornell University;   Karyopharm Therapeutics Inc
    Recruiting

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Glioma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide Phosphate;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Daratumumab;   Drug: Cisplatin;   Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Melphalan;   Procedure: ASCT;   Drug: Lenalidomide;   Drug: Bortezomib
    Sponsors:   University of Arkansas;   Janssen, LP
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Intervention:   Drug: Pentamidine
    Sponsor:   University of Kentucky
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Condition:   Recurrent Adult Hodgkin Lymphoma
    Interventions:   Biological: basiliximab;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: yttrium Y 90-labeled basiliximab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: bendamustine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Bleomycin;   Drug: Vincristine;   Drug: Vinblastine;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: DTIC;   Other: Quality of Life Measurements;   Radiation: Radiotherapy
    Sponsors:   St. Jude Children's Research Hospital;   Teva Pharmaceuticals USA;   Seattle Genetics, Inc.
    Recruiting

  • Condition:   Lung Cancer
    Interventions:   Drug: Osimertinib;   Drug: Platinum;   Drug: Etoposide
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma;   Neuroendocrine Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Procedure: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Indolent Non-Hodgkin Lymphoma;   Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Nivolumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Kami Maddocks;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Atovaquone;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Drug: Gemtuzumab Ozogamicin
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   William Marsh Rice University
    Recruiting

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation or proton beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
    Interventions:   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis;   Drug: Anti-seizure prophylaxis;   Drug: Ursodiol
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   NK-Cell Lymphoma;   NK-Cell Leukemia;   Peripheral T Cell Lymphoma
    Interventions:   Drug: Methotrexate;   Drug: pralatraxate,;   Drug: Ifosfamide;   Drug: Dexamethasone;   Drug: Etoposide;   Drug: Pegaspargase;   Drug: cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Brentuximab Vedotin
    Sponsors:   New York Medical College;   University of Alabama at Birmingham
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Biological: pembrolizumab;   Drug: doxorubicin;   Drug: vinblastine;   Drug: dacarbazine;   Drug: cyclophosphamide;   Drug: vincristine;   Drug: prednisone/prednisolone;   Drug: bleomycin;   Drug: etoposide;   Radiation: Radiotherapy (RT)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: M7824;   Drug: Placebo;   Drug: Durvalumab;   Drug: Etoposide;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiation Therapy (IMRT)
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Not yet recruiting

  • Conditions:   Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Amgen
    Recruiting

  • Conditions:   Relapsed Solid Tumors;   Refractory Solid Tumors;   Leukemias
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   Phoenix Children's Hospital;   Amgen;   Pediatric Oncology Experimental Therapeutics Investigators' Consortium
    Recruiting

  • Conditions:   Childhood Germ Cell Tumor;   Ovarian Cancer;   Teratoma
    Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: paclitaxel;   Drug: thiotepa;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: Mesna;   Biological: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Cancer
    Interventions:   Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
    Sponsor:   Emory University
    Recruiting

  • Condition:   Lung
    Interventions:   Radiation: SBRT;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: cis Platinum;   Drug: Etoposide;   Radiation: IMRT
    Sponsor:   Atrium Health
    Recruiting

  • Conditions:   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Angioimmunoblastic T-Cell Lymphoma;   CD30-Positive Neoplastic Cells Present;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage III Anaplastic Large Cell Lymphoma;   Stage IV Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin;   Drug: Nelarabine
    Sponsors:   St. Jude Children's Research Hospital;   Bristol-Myers Squibb;   Incyte Corporation;   Shire
    Recruiting

  • Conditions:   Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Sex Cord-Stromal Tumor;   Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types;   Ovarian Steroid Cell Tumor
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Gastric Neuroendocrine Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
    Recruiting

  • Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Radiation: Thoracic Radiotherapy;   Drug: Platinum Based Chemotherapy;   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Conditions:   Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma;   Primary CNS Tumor
    Interventions:   Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   NewLink Genetics Corporation
    Recruiting

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane;   Drug: ^1^1C-methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Lymphocyte-Rich Classical Hodgkin Lymphoma;   Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Recurrent Mixed Cellularity Classical Hodgkin Lymphoma;   Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma;   Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Refractory Mixed Cellularity Classical Hodgkin Lymphoma;   Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Paranasal Sinus Cancer;   Nasal Cavity Tumor;   Nasal Cavity Adenocarcinoma
    Interventions:   Drug: Cisplatin;   Radiation: Adjuvant Proton Radiotherapy;   Procedure: Endoscopic Resection;   Drug: cisplatin and etoposide
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
    Interventions:   Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus;   Other: Observation Only
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Immature Ovarian Teratoma;   Grade 3 Immature Ovarian Teratoma;   Malignant Germ Cell Tumor;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma;   Stage I Ovarian Teratoma;   Stage I Ovarian Yolk Sac Tumor;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma;   Stage II Ovarian Yolk Sac Tumor;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma;   Stage III Ovarian Yolk Sac Tumor;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma;   Stage IV Ovarian Yolk Sac Tumor;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-hodgkin Lymphoma
    Intervention:   Drug: Venetoclax
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   AIDS-Related Lymphoma;   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   CD20 Negative;   CD20 Positive;   Human Immunodeficiency Virus Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
    Interventions:   Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment of Cancer - EORTC;   Movember Foundation;   Institute of Cancer Research (ICR), United Kingdom;   Cancer Research UK;   UNICANCER;   Irish Group CTI
    Recruiting

  • Conditions:   Medulloblastoma;   Central Nervous System Embryonal Tumors
    Interventions:   Drug: Induction;   Drug: Single Cycle Intensive Chemotherapy;   Drug: Tandem 3 Cycle Intensive Chemotherapy
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital Los Angeles
    Recruiting

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Tislelizumab;   Drug: Concurrent chemoradiotherapy (cCRT);   Other: Placebo
    Sponsors:   Celgene;   BeiGene
    Recruiting

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Large B-Cell Diffuse Lymphoma
    Interventions:   Drug: Oral azacitidine;   Drug: R-ICE
    Sponsors:   Medical University of South Carolina;   Celgene Corporation
    Recruiting

  • Condition:   Peripheral T Cell Lymphoma
    Intervention:   Drug: Nivolumab and EPOCH
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Doxorubicin Hydrochloride
    Sponsors:   Weill Medical College of Cornell University;   Genentech, Inc.;   Massachusetts General Hospital;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Newly Diagnosed Ewing Sarcoma
    Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Drug: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan;   Drug: Mesna;   Drug: Dexrazoxane;   Drug: G-CSF
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   NorthShore University HealthSystem;   University of Rochester;   Medical College of Wisconsin;   University of Nebraska;   Sanofi;   University Hospitals Seidman Cancer Center
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: ITMHA;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Vincristine
    Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research;   Texas Children's Hospital
    Recruiting

  • Condition:   T Cell Non-Hodgkin Lymphoma
    Intervention:   Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
    Sponsors:   Memorial Sloan Kettering Cancer Center;   University of Washington;   Weill Medical College of Cornell University;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ann Arbor Stage IIB Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Childhood Hodgkin Lymphoma;   Classic Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Biological: Durvalumab;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Pemetrexed Disodium;   Radiation: Photon Beam Radiation Therapy;   Radiation: Proton Beam Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting

  • Conditions:   Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
    Interventions:   Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Millennium Pharmaceuticals, Inc.;   Takeda Pharmaceuticals U.S.A., Inc.
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics LLC.
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Papillary Ependymoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Advanced Solid Tumor
    Interventions:   Drug: M6620;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia, Pediatric
    Interventions:   Drug: Pegaspargase;   Drug: Erwinia asparaginase;   Drug: Cyclophosphamide;   Drug: CYTARABINE;   Drug: DASATINIB;   Drug: DEXAMETHASONE;   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: ETOPOSIDE;   Drug: HYDROCORTISONE;   Drug: LEUCOVORIN CALCIUM;   Drug: MERCAPTOPURINE;   Drug: METHOTREXATE;   Drug: NELARABINE;   Drug: Vincristine
    Sponsors:   Dana-Farber Cancer Institute;   Shire
    Recruiting

  • Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
    Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   EpicentRx, Inc.
    Recruiting

  • Conditions:   Carcinoma, Squamous Cell of Head and Neck;   Carcinoma, Non-Small-Cell Lung;   Small Cell Lung Carcinoma
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Cisplatin (dose level 4);   Drug: Cisplatin (dose level 3);   Drug: Carboplatin (dose level 1);   Drug: Carboplatin (dose level 2);   Drug: Etoposide (dose level 1);   Drug: Etoposide (dose level 2);   Drug: Paclitaxel;   Drug: Pemetrexed;   Radiation: External beam radiation (dose level 1);   Radiation: External beam radiation (dose level 2);   Radiation: External beam radiation (hyperfractionated);   Drug: Cisplatin (dose level 1);   Drug: Cisplatin (dose level 2);   Radiation: External beam radiation (standard)
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Medulloblastoma
    Interventions:   Drug: Bevacizumab;   Drug: Thalidomide;   Drug: Celecoxib;   Drug: Fenofibric acid;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Cytarabine
    Sponsor:   Medical University of Vienna
    Recruiting

  • Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Uproleselan;   Drug: Placebo
    Sponsor:   GlycoMimetics Incorporated
    Recruiting

  • Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting

  • Condition:   Recurrent Glioblastoma
    Interventions:   Diagnostic Test: ChemoID assay;   Drug: Chemotherapy
    Sponsor:   Cordgenics, LLC
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Neuroblastoma
    Interventions:   Drug: chemotherapy;   Drug: venetoclax
    Sponsors:   AbbVie;   Roche-Genentech
    Recruiting

  • Conditions:   Primary Effusion Lymphoma;   B-Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Richter Syndrome
    Interventions:   Drug: Venetoclax;   Other: DA-EPOCH-R
    Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute
    Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
    Sponsor:   Actinium Pharmaceuticals
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

Login to Get Started